CHD-PAH is a major cause of morbidity and mortality, highlighting the importance of early recognition and surgical treatment to prevent pulmonary vascular disease.
PAH prevalence in CHD survivors supports vigilant monitoring; leaves open optimal prevention strategies with modern surgical care.
Pulmonary arterial hypertension associated with congenital heart disease (CHD-PAH), as discussed throughout this issue of Advances in Pulmonary Hypertension, is one of the most commonly occurring causes of significant or severe morbidity and untimely mortality in CHD patients.1 Without surgical therapy, it is suggested that some 30% of CHD patients will develop PAH.2 Early recognition and treatment of CHD is often discussed, therefore, as the most effective preventive treatment measure for patients at risk for pulmonary vascular disease. Epidemiologic estimates of occur-rence of CHD-PAH have targeted approximately 15% of all CHD survivors as having PAH.3
No takes yet. Share an insight, caveat, or question.
Michael J. Landzberg (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: